Bloomsbury Publishing to Publish Memoir by Broadway Choreographer Larry Fuller
Bloomsbury Publishing has announced it will publish 'Dancing Through Life: A Broadway Memoir of Luck & Talent' by Larry Fuller in May 2027.
Stocks · News reference
Beeline Medicines Reports Phase 2 Results for Afimetoran, a Bristol Myers Squibb-Discovered Therapy
Beeline Medicines Corporation announced Phase 2 study results for afimetoran, an investigational TLR7/8 inhibitor originally discovered by Bristol Myers Squibb.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aberdeen Group plc Reduces Voting Stake in Bloomsbury Publishing plc
Aberdeen Group plc has notified Bloomsbury Publishing plc that its voting rights in the company have fallen below the 5% threshold.
Bristol Myers Squibb Triggers Milestone Payment to Editas Medicine
Bristol Myers Squibb has triggered a clinical development milestone payment to Editas Medicine, as reported in the latter's third-quarter 2026 financial update.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027
BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.
Bristol Myers Squibb Presents 56-Week Phase 3 Data for Camzyos in Pediatric Patients with Symptomatic oHCM
Bristol Myers Squibb presented 56-week Phase 3 clinical trial data for Camzyos (mavacamten) in pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy at the HCMS Scientific Sessions.